Scanner with improved functionality installed
A life science consultant from TTP plc has delivered the next version of the Lumito’s scanner, with improved functionality, and assisted in the installation process. The new scanner entails, among other things, greater capacity to test new indications and to complete the evaluation of the breast cancer marker Her2. – Due to the pandemic, this was […]
Patent application approved in an additional country – Brazil
Lumito's (https://lumito.se/en/home/) basic patent, a patent in the first patent family protecting the use of upconverting nanoparticles (UCNPs) for imaging in scattering materials, such as human tissue, has now been approved in Brazil. Among other countries, the company is awaiting response to an application concerning India. – The approval of our basic patent is an important […]
Lumito develops the tissue diagnostics of the future – basic patent now granted in Europe
Lumito's product comprises an instrument and staining reagents based on UCNPs (up-converting nanoparticles). The instrument is intended for use in tissue diagnostics, to provide pathologists visual depictions of tissue samples as an input for making diagnosis. The technology is patented across three global patent families that cover the creation of high-quality imaging of tissue, for […]
Lumito AB publishes Quarterly Report 2, 2021
Financial overview of the second quarter and the half year Second quarter 2021, April 1 – June 30 Net sales amounted to KSEK 0 (0). Result after taxes amounted to KSEK -6 619 (-4 202). Earnings per share before and after dilution amounted to SEK -0.08 (-0.06). Cash flow from operating activities after changes in […]
Patent approved also in India
The patent describing the use of light pulses to improve the efficiency of the technique and shorten imaging times has now also been granted in India. The patent has already been approved in Europe, South Korea, Australia, China, South Africa, USA and Japan and we are awaiting approval in Canada. – The grant of the […]
Processes in place for ISO 13485 qualification
Confirmation from an independent auditing company now shows that Lumito has the processes in place to qualify for ISO 13485. The first step has been passed and the next step in the process is for the company to demonstrate that the processes are being followed in practice. The processes reflect that the company is well […]
Lumito AB Quarterly Report (1 Jan to 31 March) 2021
Significant events during the first quarter of 2021 Lumito’s advisors in the field of pathology have had the opportunity to review the company’s UCNP immunostaining of invasive breast cancer with an antibody against HER2 (the target molecule) at a high image resolution. “The signals are uniquely sharp and clear, which gives the impression of staining […]
Lumito AB publishes Quarterly Report 1, 2021
Financial overview for the first quarter January 1st to March 31st, 2021 • Net sales amounted to SEK 0 (0) thousand • Profit after tax amounted to SEK -6,825 (-2,795) thousand. • Earnings per share before and after dilution amounted to SEK -0.08 (-0.04). • Cash flow from operating activities after changes in working capital […]
Lumito publishes Year-end Report for 2020
Financial overview 2020 Financial overview of the fourth quarter, 1 October – 31 December 2020. Net sales amounted to kSEK 0 (0). Result after taxes amounted to kSEK -5,200 (-2,545). Basic and diluted earnings per share amounted to SEK -0.06 (-0.04) Cash flow from operating activities amounted to kSEK -5,198 (-3,145). Financial overview of the […]
Lumito initiates process for listing on Nasdaq First North Growth Market
The Lund-based medical device company Lumito AB has initiated a process to list the Company's shares and warrants on Nasdaq First North Growth Market. As part of this process, a conditional application for delisting from NGM Nordic SME has been submitted to NGM. The application is conditional on Nasdaq’s approval of Lumito for listing on […]
